Heartland Advisors Inc. cut its stake in Haemonetics Corporation (NYSE:HAE) by 33.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 165,494 shares of the medical instruments supplier’s stock after selling 82,180 shares during the period. Heartland Advisors Inc. owned about 0.32% of Haemonetics Corporation worth $6,535,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. State of Alaska Department of Revenue boosted its position in shares of Haemonetics Corporation by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 5,740 shares of the medical instruments supplier’s stock valued at $232,000 after buying an additional 130 shares in the last quarter. US Bancorp DE boosted its position in shares of Haemonetics Corporation by 0.6% in the second quarter. US Bancorp DE now owns 22,154 shares of the medical instruments supplier’s stock valued at $875,000 after buying an additional 141 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Haemonetics Corporation by 1.3% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,800 shares of the medical instruments supplier’s stock valued at $479,000 after buying an additional 150 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Haemonetics Corporation by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the medical instruments supplier’s stock valued at $845,000 after buying an additional 200 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in shares of Haemonetics Corporation by 0.9% in the first quarter. Envestnet Asset Management Inc. now owns 25,371 shares of the medical instruments supplier’s stock valued at $1,028,000 after buying an additional 225 shares in the last quarter.

Shares of Haemonetics Corporation (NYSE:HAE) opened at 43.61 on Friday. Haemonetics Corporation has a 12-month low of $32.76 and a 12-month high of $43.74. The firm has a market capitalization of $2.29 billion, a PE ratio of 566.36 and a beta of 0.88. The company’s 50 day moving average is $41.37 and its 200 day moving average is $40.50.

Haemonetics Corporation (NYSE:HAE) last posted its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The business had revenue of $211 million during the quarter, compared to analysts’ expectations of $211.29 million. During the same period in the prior year, the business earned $0.25 EPS. Haemonetics Corporation’s revenue for the quarter was up .5% compared to the same quarter last year. On average, analysts forecast that Haemonetics Corporation will post $1.60 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/09/02/heartland-advisors-inc-sells-82180-shares-of-haemonetics-corporation-hae.html.

HAE has been the topic of several analyst reports. Zacks Investment Research downgraded shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. JMP Securities raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Thursday, July 13th. Jefferies Group LLC reissued a “buy” rating and issued a $48.00 target price on shares of Haemonetics Corporation in a research report on Thursday, July 27th. Finally, BidaskClub raised shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. Haemonetics Corporation has an average rating of “Hold” and an average price target of $40.71.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.